**Supplementary Table 1** Characteristics of HIV-hepatitis C virus cohort participants at cohort entry and last visit according to cause of death

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Total  (n = 1634) | Death  (n = 273) | Alive  (n = 1361) | ESLD  (n = 46) | Smoking  (n = 41) | Overdose  (n = 49) | Other  (n = 83) | Unknown  (n = 54) |
| **Follow-up time, median (IQR) (years)** | 4.3 (2.2, 8) | 3.4 (1.5, 6.1) | 4.5 (2.3, 8.2) | 3.4 (1.6, 5.7) | 3.4 (2.4, 5.3) | 2.2 (1, 6.2) | 4.7 (2, 7.1) | 3.1 (1.3, 5.3) |
|  | **Characteristics at cohort entry** | | | | | | | |
| **Age, median (IQR) (years)** | 45 (39, 51) | 47 (43, 53) | 45 (38, 51) | 47 (44, 53) | 51 (44, 56) | 45 (41, 48) | 48 (44, 54) | 46 (42, 54) |
| **Female, no. (%)** | 451 (28) | 76 (28) | 375 (28) | 13 (28) | 5 (12) | 17 (35) | 21 (25) | 20 (37) |
| **Aboriginal, no. (%)** | 364 (22) | 51 (19) | 313 (23) | 10 (22) | 5 (12) | 10 (20) | 18 (22) | 8 (15) |
| **Greater than high school education, no. (%)** | 437 (27) | 68 (25) | 369 (27) | 12 (26) | 12 (29) | 12 (24) | 22 (27) | 10 (19) |
| **Gross monthly income <$1500, no. (%)** | 1233 (75) | 214 (78) | 1019 (75) | 35 (76) | 30 (73) | 41 (84) | 62 (75) | 46 (85) |
| **History of IDU, no. (%)** | 1319 (81) | 233 (85) | 1086 (80) | 34 (74) | 35 (85) | 48 (98) | 66 (80) | 50 (93) |
| **Active IDU, no. (%)** | 582 (36) | 98 (36) | 484 (36) | 17 (37) | 11 (27) | 24 (49) | 29 (35) | 17 (31) |
| **History of alcohol use, no. (%)** | 1496 (92) | 243 (89) | 1253 (92) | 41 (89) | 39 (95) | 43 (88) | 75 (90) | 45 (83) |
| **Current alcohol use, no. (%)** | 847 (52) | 124 (45) | 723 (53) | 17 (37) | 18 (44) | 17 (35) | 43 (52) | 29 (54) |
| **History of smoking, no. (%)** | 1476 (90) | 257 (94) | 1219 (90) | 41 (89) | 40 (98) | 49 (100) | 74 (89) | 53 (98) |
| **Current smoker, no. (%)** | 1210 (74) | 215 (79) | 995 (73) | 35 (76) | 31 (76) | 41 (84) | 61 (73) | 47 (87) |
| **Time since HIV diagnosis, median (IQR) (years)** | 11 (5.7, 18) | 11 (6.5, 17) | 11 (5.6, 18) | 11 (8.1, 15) | 12 (5.8, 18) | 12 (6.2, 16) | 11 (7.5, 18) | 11 (4.3, 15) |
| **Prior AIDS diagnosis, no. (%)** | 403 (25) | 86 (32) | 317 (23) | 17 (37) | 17 (41) | 17 (35) | 22 (27) | 13 (24) |
| **Nadir CD4+ cell count, median (IQR) (cells/ml)** | 177 (80, 294) | 136 (60, 230) | 184 (86, 300) | 110 (50, 196) | 158 (75, 214) | 130 (75, 311) | 138 (55, 240) | 140 (83, 230) |
| **CD4+ cell count, median (IQR) (cells/ml)** | 400 (250, 580) | 319 (190, 510) | 418 (269, 595) | 235 (148, 344) | 272 (225, 570) | 345 (191, 511) | 384 (180, 530) | 337 (220, 540) |
| **HCV RNA positive, no. (%)** | 1322 (81) | 219 (80) | 1103 (81) | 34 (74) | 30 (73) | 41 (84) | 70 (84) | 44 (81) |
| **HIV RNA <50 copies/ml, no. (%)** | 1009 (74) | 150 (67) | 859 (76) | 26 (65) | 25 (71) | 22 (61) | 49 (68) | 28 (68) |
| **On cART, no. (%)** | 1361 (83) | 224 (82) | 1137 (84) | 40 (87) | 35 (85) | 36 (73) | 72 (87) | 41 (76) |
| **cART-naive, no. (%)** | 141 (8.6) | 26 (9.5) | 115 (8.4) | 2 (4.3) | 5 (12) | 4 (8.2) | 7 (8.4) | 8 (15) |
| **Duration HCV infection, median (IQR) (years)** | 18.3 (10, 26) | 21 (12, 28) | 17.7 (9.4, 26) | 21.1 (14, 27) | 24.5 (12, 34) | 21.8 (16, 25) | 18.7 (12, 28) | 20.2 (11, 27) |
| **HCV treatment naive, no. (%)** | 1317 (81) | 228 (84) | 1089 (80) | 38 (83) | 33 (80) | 44 (90) | 66 (80) | 47 (87) |
| **HCV genotype (1 and 4), no. (%)** | 1017 (62) | 155 (57) | 862 (63) | 27 (59) | 18 (44) | 30 (61) | 52 (63) | 28 (52) |
| **APRI > 1.5, no. (%)** | 307 (19) | 77 (28) | 230 (17) | 31 (67) | 7 (17) | 8 (16) | 20 (24) | 11 (20) |
| **Prior ESLD diagnosis, no. (%)** | 142 (8.7) | 48 (18) | 94 (6.9) | 24 (52) | 3 (7.3) | 4 (8.2) | 10 (12) | 7 (13) |
|  | **Characteristics at last visit** | | | | | | | |
| **Age, median (IQR) (years)** | 50 (43, 56) | 50 (45, 56) | 50 (43, 56) | 50 (45, 55) | 53 (47, 58) | 48 (43, 53) | 53 (47, 58) | 49 (45, 55) |
| **Active IDU, no. (%)** | 464 (28) | 85 (31) | 379 (28) | 9 (20) | 9 (22) | 25 (51) | 23 (28) | 19 (35) |
| **Alcohol use, no. (%)** | 920 (56) | 130 (48) | 790 (58) | 15 (33) | 22 (54) | 30 (61) | 38 (46) | 25 (46) |
| **Smoke cigarettes, no. (%)** | 1155 (71) | 213 (78) | 942 (69) | 36 (78) | 30 (73) | 42 (86) | 60 (72) | 45 (83) |
| **AIDS diagnosis, no. (%)** | 92 (5.6) | 30 (11) | 62 (4.6) | 3 (6.5) | 2 (4.9) | 7 (14) | 11 (13) | 7 (13) |
| **CD4 + cell count, median (IQR) (cells/ml)** | 480 (283, 689) | 330 (175, 530) | 500 (314, 710) | 170 (84.5, 328) | 369 (200, 540) | 415 (238, 596) | 332 (190, 540) | 362 (220, 535) |
| **HCV RNA positive, no. (%)** | 640 (39) | 138 (51) | 502 (37) | 24 (52) | 22 (54) | 27 (55) | 34 (41) | 31 (57) |
| **HIV RNA <50 copies/ml, no. (%)** | 1123 (81) | 160 (68) | 963 (83) | 29 (71) | 24 (65) | 26 (67) | 56 (78) | 25 (56) |
| **On cART, no. (%)** | 1390 (85) | 234 (86) | 1156 (85) | 41 (89) | 37 (90) | 39 (80) | 72 (87) | 45 (83) |
| **cART naive, no. (%)** | 52 (3.2) | 13 (4.8) | 39 (2.9) | 1 (2.2) | 1 (2.4) | 2 (4.1) | 5 (6) | 4 (7.4) |
| **HCV treatment naive, no. (%)** | 921 (56) | 201 (74) | 720 (53) | 33 (72) | 30 (73) | 38 (78) | 55 (66) | 45 (83) |
| **APRI > 1.5, no. (%)** | 215 (13) | 74 (27) | 141 (10) | 33 (72) | 5 (12) | 6 (12) | 19 (23) | 11 (20) |
| **ESLD diagnosis, no. (%)** | 67 (4.1) | 34 (12) | 33 (2.4) | 15 (33) | 2 (4.9) | 1 (2) | 11 (13) | 5 (9.3) |

APRI, aspartate aminotransferase-to-platelet ratio; cART, combination antiretroviral therapy; ESLD, end-stage liver disease; HCV, hepatitis C virus; IDU, injection drug use; IQR, inter-quartile range.